Research progress of PD-1/PD-L1 in ovarian cancer
10.16571/j.cnki.1008-8199.2017.01.023
- VernacularTitle:程序性死亡受体-1/配体-1在卵巢癌中的研究进展
- Author:
Xiaomei WU
;
Yue LEI
;
Xiaoyi DUAN
- Keywords:
Programmed cell death-1;
Programmed cell death-1 ligands;
Ovarian cancer
- From:
Journal of Medical Postgraduates
2017;30(1):108-112
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death-1 (PD-1), as a member of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), is ex-pressed on the membrane of activated T cells , B cells and macrophages.Combining with programmed cell death-ligand 1 (PD-L1), PD-1 will inhibit the proliferation of T cells and further involve in T cell receptor signaling negative feedback regulation .As the signifi-cant relationship between PD-1 /PD-L1 expression and prognosis in tumor cells , monocytes and T cells of ovarian cancer patients , this review focuses on the biological significance , influencing factors , advances of related drugs and clinical application of PD-1 /PD-L1 in ovarian cancer .